Annovis Bio Future Growth

Future criteria checks 0/6

Annovis Bio's earnings are forecast to decline at 3.1% per annum while its annual revenue is expected to grow at 66.7% per year. EPS is expected to grow by 46% per annum. Return on equity is forecast to be -84.1% in 3 years.

Key information

-3.1%

Earnings growth rate

46.0%

EPS growth rate

Biotechs earnings growth24.6%
Revenue growth rate66.7%
Future return on equity-84.1%
Analyst coverage

Low

Last updated13 Jun 2024

Recent future growth updates

Recent updates

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

May 02

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Feb 12

Annovis And Alzheimer's Disease: The Best-Laid Plans

Jan 30

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials

Jan 20

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts

Oct 16

Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Sep 08
Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Jun 28

Annovis wins EU nod to expand late-stage trial for Parkinson's candidate

Feb 08

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Jan 28
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug

Jan 25

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Oct 06

We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Sep 15
We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Annovis Bio announces publication of three U.S. patents covering lead asset

Sep 13

Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate

Aug 24

Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate

Jul 07

Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

May 14
Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Feb 10
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Apr 16
Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

Feb 23
Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

Jan 01
We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

Earnings and Revenue Growth Forecasts

NYSE:ANVS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268-69-58-564
12/31/2025N/A-47-47-455
12/31/2024N/A-19-24-235
3/31/2024N/A-48-35-35N/A
12/31/2023N/A-56-40-40N/A
9/30/2023N/A-42-34-34N/A
6/30/2023N/A-33-29-29N/A
3/31/2023N/A-30-26-26N/A
12/31/2022N/A-25-17-17N/A
9/30/2022N/A-24-15-15N/A
6/30/2022N/A-20-13-13N/A
3/31/2022N/A-17-10-10N/A
12/31/2021N/A-14-9-9N/A
9/30/2021N/A-10-8-8N/A
6/30/2021N/A-8-7-7N/A
3/31/2021N/A-8-5-5N/A
12/31/2020N/A-5-4-4N/A
9/30/2020N/A-4-3-3N/A
6/30/2020N/A-3-2-2N/A
3/31/2020N/A-1-1-1N/A
12/31/2019N/A-100N/A
9/30/2019N/A-1-1-1N/A
6/30/2019N/A-1-1-1N/A
3/31/2019N/A-1-1-1N/A
12/31/2018N/A-1-1-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANVS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANVS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANVS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANVS is forecast to have no revenue next year.

High Growth Revenue: ANVS is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ANVS is forecast to be unprofitable in 3 years.


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.